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Breast cancer remains a clinically challenging disease, both from the therapeutic and observa-tional points of view. It is still the most common 
malignancy in women and is increasing in incidence 
worldwide, including in Saudi Arabia.1-3 However, the 
mortality rate has seen a dramatic decline over the years 
mainly due to development of targeted therapy as well as 
improvement of early breast cancer detection.4-8 Despite 
this, a significant subgroup of patients derive little ben-
efit from treatment. This subpopulation reflects the fact 
that breast cancers are a heterogeneous group of tumors 
characterized by a wide spectrum of clinical, pathologi-
cal and molecular features.9-11 This variation of factors 
accounts for differences in response to therapy and out-
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BaCKgROunD anD OBjECtIVES: triple-negative breast cancer (tnBC) has a poor prognosis and overall 
survival (os) compared to other types of breast cancer tumors. however, there is to date no evidence that this is 
also the case in saudi arabia.
DESIgn anD SEttIng: retrospective review of breast cancer patients who were treated from January 2001 to 
December 2008 (517 patients) at the King abdulaziz medical City, riyadh, saudi arabia.
patIEntS anD mEthODS: Patients were selected as tnBC if all three markers of estrogen receptor (Er), pro-
gesterone receptor (Pr) and the human epidermal growth factor (hEr2) tested by immunohistochemistry as nega-
tive. they were then age- and stage-matched, and compared with non-tnBC patients to examine differences, if 
any, in their clinicopathologic features, prognosis and os. 
RESuLtS: twenty-six patients with a follow up time of at least three years were identified as tnBC. thirty-three 
patients who were age- and stage-matched were selected as the non-tnBC controls. Clinicopathologic results 
illustrated significantly more grade 3 tumors (P=.02) and CK 5/6 expression (P<.001) in the tnBC group com-
pared to the non-tnBC group. tnBC patients aged ≤40 years showed a significantly worse prognosis and os 
compared to tnBC patients aged >40 years (P=.01), and when compared to the non-tnBC group (P=.04).
COnCLuSIOn: the incidence of tnBC in our cohort is similar to what has been illustrated in previous studies 
in Western population. there was no significant difference in 3-year survival between tnBC and non-tnBC 
groups. however, the aggressiveness of this type of tumor and os is significantly higher in younger patients aged 
≤40 years, compared to those over 40 years of age.
comes among women diagnosed with breast cancers.12-14
Gene expression profiling and immunohistochemi-
cal expression have shown that breast cancer can be 
classified into biologically distinct subtypes.9,11,15 Triple-
negative breast cancer (TNBC) has drawn particular 
attention since it lacks targeted therapies and patients 
do not benefit from anti-estrogen hormonal therapy 
or trastuzumab.16 Some groups have shown limited re-
sponse of TNBC patients with non-adjuvant therapy.17 
More recent studies have shown that TNBC patients, 
that are also node-negative, have a greater benefit with 
chemotherapy than with no chemotherapy at all.18 As 
these studies only show benefit for a small subset of pa-
tients, TNBC still remains a clinical challenge. 
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TNBC is an aggressive subtype that accounts for 10% 
to 15% of all breast cancer cases.19 It is frequently identi-
fied by conventional immunohistochemical techniques, 
as these tumors lack staining for the estrogen receptor 
(ER), progesterone receptor (PR), and the human epi-
dermal growth factor (HER2).20 Moreover, triple-nega-
tive (TN) tumors are often positive for cytokeratin (CK) 
5/6, are typically high grade, and have a higher risk of 
relapse within the first several years after initial diagno-
sis.21-23 Aside from the established pathologic variables 
mentioned above, tumor size and p53 status also have 
specific prognostic value in TNBC. Positive staining for 
p53, for example, results in poor survival expectancy for 
these patients.21,24 The immunohistochemical surrogates 
of TN tumors, the absence of ER, PR and HER2 and 
positivity for CK 5/6 and p53, are important breast can-
cer specific markers that have been commonly used to 
identify the TNBC.22,24,25 This approach is applicable to 
standard pathology specimens and has sensitivity of 76%, 
and specificity up to 100%.26 In addition, TNBC are as-
sociated with poor prognosis, younger patient age,27 poor 
relapse,11,16,28 poor Nottingham prognostic index, a high 
incidence of recurrence and metastasis,29-31 poor overall 
survival and poor overall outcome32-35 compared to other 
types of breast cancer. Furthermore, a higher percentage 
of visceral metastases, local relapse and cerebral metasta-
sis occur in TNBC.29-31,36 
The clinicopathologic features and prognostic factors 
of TNBC have been thoroughly studied in the Western 
population. However, few studies have been conducted 
among the non-Western ethnic groups.37-40 We therefore 
decided to investigate whether the same factors are ap-
plicable to Saudi TNBC patients. Hence this present 
retrospective analysis was undertaken to firstly compare 
the clinicopathologic features and prognosis of TNBC 
patients versus the non-TNBC patients diagnosed in 
King Abdulaziz Medical City (KAMC), Riyadh, Saudi 
Arabia, as a single institution experience. Secondly, we 
examined outcome differences, if any, within the TNBC 
and non-TNBC groups, using 40 years as a cut-off age.
patIEntS anD mEthODS
A retrospective analysis was conducted of the clini-
copathologic features of TNBC patients undergoing 
surgery at KAMC (a single institution), Riyadh, Saudi 
Arabia. Data was first collected on all female patients 
with breast cancer diagnosed at the hospital between 
January 2001 and December 2008. Five hundred and 
seventeen pathologically proven breast cancer patients 
were identified with data available on tumor grade and 
stage, level of ER, PR and HER2 expression, patient age 
at diagnosis, ethnicity, site of tumor, risk factors, present-
ing symptoms, clinical findings on presentation, radio-
logical findings, and the method of treatment. Before sur-
gery, all patients were evaluated through standard staging 
procedures which included complete physical examina-
tion, chest radiography as well as CT chest scan, bilateral 
mammography, ultrasound of the breasts, abdominal ul-
trasound and routine blood work. After complete stag-
ing workup, patients were treated according to standard 
treatment protocol after discussion of the tumor board. 
Follow-up information regarding tumor recurrence and 
survival status, including reason for death, was accom-
plished through the retrieval of medical records. 
Data was collected from a total of 517 breast cancer 
patients who underwent a complete staging workup pri-
or to final management at our institution. Patients were 
then categorized based on their immunohistochemical 
staining results for expression of the three markers ER, 
PR, and HER2. All patients selected had complete ex-
amination and treatment data, with a follow-up of at 
least three years.
The TNBC group consisted of 26 patients that 
tested negative for ER, PR and HER2 expression, and 
therefore were deemed TN. This group was further cat-
egorized into two sub-groups, those aged >40 years and 
those ≤40 years, to compare prognosis with age. The non-
TNBC group consisted of 33 cases selected from the to-
tal breast cancer cases that were age- and stage-matched 
to the TNBC group, and whose immunohistochemical 
staining were positive for at least one of the three mark-
ers. This group was classed as the control group.
Slides for the TNBC and non-TNBC study popu-
lation tumors were retrieved and reviewed again by one 
pathologist to collect pathological features. Tumors were 
regraded according to the Scarff-Bloom-Richardson 
grading system, and the tumor histological types and 
features were assessed. Immunohistochemically stained 
slides for ER, PR, and HER2 of the study tumors were 
reviewed and re-assessed to confirm the original diagno-
sis of either TNBC or non-TNBC. In those cases that 
lacked stained slides in the pathology files, serial 4 µm 
sections from selected paraffin blocks of the study tu-
mors were cut and stained for ER, PR, HER2, p53 and 
CK 5/6 on an automated system (Ventana, Tucson, AZ, 
USA), as per the manufacturer’s instructions. Primary 
antibody suppliers and dilutions for the immunohisto-
chemical analysis were as follows: ER (Labvision, clone 
SP1, dilution 1:200), PR (Labvision, clone SP2, dilution 
1:400), HER2 (Ventana, clone 4B5, dilution 1:200), p53 
(Dako, clone DO-7, dilution 1:400), CK 5/6 (Dako, 
clone DS-16B4, dilution 1:100). Immunohistochemical 
scoring of ER, PR and HER2 followed the ASCO/CAP 
guidelines (www.asco.org/guidelines/erpr).
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The differences in pathological features, immune-
marker expressions, histopathological, immunohisto-
chemical and clinical features in the two study groups 
were compared using the chi-square statistics or the 
Fisher exact test. Overall survival (OS) between the 
TNBC and non-TNBC groups was calculated from the 
date of diagnosis of breast cancer to date of death from 
any cause or last follow up. The Kaplan-Meier and the 
log-rank test methods were used to construct and com-
pare survival curves. Cox hazard regression models were 
fitted to determine factors associated with mortality. All 
tests were two-sided and a P-value <.05 was considered 
significant. SPSS (version 19) was used for data analysis.
RESuLtS
Data for 517 breast cancer patients were found that 
were treated at KAMC and 62 patients from this cohort 
(12%) were identified as having TNBC, where their 
immunohistochemical staining tested negative for the 
ER, PR and HER2 markers. From these, 26 patients 
of Saudi origin were selected as the TNBC group since 
follow-up data was also available 2 years after diagno-
sis (mean time between diagnosis and follow up was 36 
months). For the control non-TNBC group, a total of 
33 patients were chosen based on age and tumor stage 
matching to the TNBC group, and who tested positive 
for at least one of the markers. This cohort therefore in-
cluded 59 patients in total; 26 TNBC patients and 33 
non-TNBC patients. The mean age of the total sample 
was 44.4 years (standard deviation 12.3, median age 42 
years) and ranged from 24-84 years, and 45.8% of the 
sample was ≤40 years of age. The P value of the mean 
age between the TNBC and non-TNBC groups was 
not significant (45.8 and 43.2, respectively, P=.426). 
When available, data was also collected for p53 
over-expression and CK 5/6 expression for each group 
of patients. As expected, a larger proportion of TNBC 
patients showed p53 over-expression than the non-TN-
BC patients (Table 1), though this was not statistically 
significant (P=.23). In particular, statistically more CK 
5/6 expression was seen in the TNBC compared to the 
control group (P<.0001), showing a clear difference in 
expression patterns between the two groups. Consistent 
with TNBC tumors having a more aggressive morphol-
ogy, patients with TNBC had a a higher grade of tumor: 
87.3% of all TNBC tumors were of grade 3, compared 
with 56% in non-TNBC tumors (P=.02, Table 1). 
Despite this difference in tumor morphology, there was 
no statistically significant difference in overall survival 
between the two groups. 
The hazard ratio was then calculated to examine the 
relative risk between those TNBC patients aged ≤40 
years against those of >40 years (Table 2). Patients 
with TNBC aged ≤40 years had a significantly higher 
hazard ratio of death compared with those above this 
age (P=.001). In addition, survival in this younger sub-
group was significantly lower compared to TNBC aged 
>40 years (Figure 1). Similarly, when compared to the 
control-TNBC group, the TNBC aged ≤40 years also 
showed a lower rate of survival (P=.04, data not shown). 
No other factors such as tumor grade or CK5/6 expres-
sion, were associated with the hazard ratio between 
these two age groups (Table 2).
DISCuSSIOn
Breast cancers are known to be heterogeneous, and are 
characterized by a wide spectrum of clinical, pathologi-
cal, and molecular characteristics that comprise a num-
ber of recognized biological subtypes.9 TN account for 
10% to 20% of breast carcinomas. The terms TNBC 
and basal-like breast cancer (BBC) are often used in-
terchangeably by clinicians although they are not iden-
tical. Importantly, not all BBCs are TNBCs; TNBCs 
constitutes approximately 85% of all BBCs.9-12 Thus, 
whereas most TNBCs are basal-like, TN and BBC are 
not synonymous.41 Studies have shown that women 
Table 1. Baseline characteristics and mortality in patients with 
triple-negative breast cancer (TnBC, n=26) compared with 
control non-triple-negative breast cancer (non-TnBC, n=33) 
patients.
  Variable TNBC Non-TNBC P
  Age
    ≤40 years 10 (38.5) 17 (51.5)
.32
    >40 years 16 (61.5) 16 (48.5)
  Grade 3 tumor 
    Yes 21 (87.3) 14 (56.0)
.02
    no 3 (12.5) 11 (44.0)
  P53 over expression
    Yes 11 (52.4) 6 (33.3)
.23
    no 10 (47.6) 12 (66.7)
  CK5/6 expression
    Yes 15 (62.5) 3 (12.0)
<.0001
    no 9 (37.5) 22 (88.0)
  Died
    Yes 11 (42.3) 11 (33.3)
.48
    no 15 (57.7) 22 (66.70
Values are number (percent). p by χ2 test.
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with TNBC are at a higher likelihood of relapse and 
have an associated overall poor survival outcome com-
pared with women with other subtypes of breast can-
cer.16,28,32,33 Based on these points and coupled with the 
lack of available data on non-Western countries, we em-
barked on this retrospective analysis to study TNBC in 
Saudi Arabia. We compared the prognosis and clinico-
pathologic features of TNBC versus non-TNBC in our 
patients, as well as the outcome differences within the 
two groups using 40 years as a cut-off age.
In the present study, we found a higher percentage of 
the TNBC patients expressed grade 3 tumors (87.3%) 
compared to the control non-TNBC group. These propor-
tions are similar to what has been reported elsewhere (66% 
TNBC compared with 28% in other breast cancers),20 
and are consistent with estimates stating that TNBC tu-
mors are of higher grade. The aggressiveness of this type 
of breast cancer and its highly proliferating nature, means 
that it also tends to be diagnosed at a later stage.28 
Other established pathologic variables, including CK 
5/6 and p53 expression status have a specific prognostic 
value in TNBC.21,24,26 We have found statistically sig-
nificant over-expression of CK 5/6 in our TNBC group 
compared to the control group. This finding supports 
previous studies that have shown basal-like tumors are 
immunohistochemically negative for ER and HER2, but 
positive for basal CK 5/6. Eighty percent of our TNBC 
patients expressed CK 5/6, a percentage that is much 
higher than those reported by other investigators where 
expression of basal cytokeratins CK5/6 and/or CK14 
was detected in 55.7% of their TN tumors.21 Though 
not statistically significant, our results also showed pro-
portionally more p53 over-expression in TNBC than 
non-TNBC patients. A larger cohort of patients would 
enable us to confirm this finding. Our results, however, 
do provide strong evidence to support the established 
use of biomarker surrogates ER, PR and HER2 as clini-
cal tools to define all TNBC, and CK 5/6 to help refine 
the TNBC subtypes, with high specificity;25,26 a finding 
of immediate relevance to prognostication. 
Our data show that there is no significant difference 
in the overall survival (OS) between the TNBC and the 
non-TNBC tumors that are age- and stage-matched. 
However, the evidence differs from one study to another. 
For instance, consistent with our data, another study 
showed that, regardless of stage at diagnosis, women with 
TNBC had a shorter OS than those with other breast 
cancers.28 In addition, it has also been shown that TNBC 
patients have a worse prognosis,30 and that there is short-
er survival among ER and basal-like subtypes.11,19,28 On 
the other hand, another study showed that there was no 
significant differences in 5-year survival between TNBC 
Table 2. Cox-regression hazard regression analysis for factors 
associated with death in triple-negative breast cancer patients 
(TnBC).
  Characteristics Hazard Ratio(95% CI) P
  Patient groups
     TnBC 1.49 (0.64-3.44)
.36
     non-TnBC 1
  Age
     ≤ 40 years 5.43 (1.94-15.2)
.001
     ≥ 40 years 1
  Grade 3 tumor
     Yes 2.52 (0.30-21.27)
.40
     no 1
   p53 over-expression
     Yes 1.81 (0.62-5.26)
.28
     no 1
  CK5/6 expression
     Yes 1.74 (0.70-4.33)
.23
     no 1
p by Wald test
Figure 1. Survival in TnBC patients ≤40 vs >40 years of age 
(P<.001).
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cancers and other breast cancers.42 Further studies have 
shown that the difference between the TNBC and non-
TNBC groups peaked at 3 years, though this difference 
decreased with time, suggesting that long-term survivors 
(beyond 10 years) in the TNBC group may have com-
parable survival to non-TNBC cases.20,25 It is therefore 
clear that cancer-specific survival differs by subtype. Even 
within a group defined by high grade and expression of 
basal markers there is considerable heterogeneity of out-
come.43 Though we find no difference in OS between 
TNBC and non-TNBC patients after three years of fol-
low up, perhaps a larger number of cases and a follow-
up of at least 5 years would have yielded different results 
between both groups.
Our most intriguing result was the effect of age on 
the prognosis of our TNBC patients. When we closely 
analyzed and segregated our patients based on age, we 
found that TNBC patients aged ≤40 years had a sta-
tistically worse prognosis and OS compared to TNBC 
patients >40 years. In addition, a similar result was seen 
when these younger patients were compared to all of 
the non-TNBC patients. Other studies have suggested 
that, among TNBC patients, disease-free survival was 
significantly correlated with the menopausal status, 
where premenopausal status might reflect an unfavor-
able prognosis in TNBC.44 Our finding of poor survival 
in patients aged ≤40 years, coupled with the previous 
data highlights the direct relation between age and OS 
of the patients. In addition, we uncovered a new associa-
tion between the age in TNBC patients and unfavorable 
prognosis. Our results have an important implication, 
indicating that young women with TNBC tumors may 
be an ideal cohort to target in clinical trials and therefore 
may be an important avenue for future research. The ex-
tent to which the menopausal status contributes to the 
behavior of TNBC in Saudi patients and the natural 
history of the TNBC subtype in the identified age group 
(≤40 years) are areas of active research. 
We acknowledge that our study has a number of 
limitations inherent to most retrospective studies. 
Potential limitations include a relatively small sample 
size, lack of data on the menopausal status of our cases 
and our comparison of prognosis between both groups 
at 3 years of follow up only. These limitations, however, 
are balanced by the strengths of providing unique data 
to Saudi Arabia, a data extraction review and re-assess-
ment of tumors by a single pathologist, and therefore 
a consistent and single-institution approach to patho-
logical diagnosis and patient care, and finally inclusion 
of a wide range of ages. These strengths contributed to 
our database, confirming many previously established 
comparisons between TNBC and non-TNBC tumors. 
Few studies have been conducted among a non-Western 
population. Having said that, our study stands on the 
strength of the fact that the observations we report from 
this database provide new insights into the Saudi popu-
lation. Our findings illustrate that our TNBC patients 
showed a similar trend to that described in others study-
ing those patients in Western countries, where the inci-
dence of TNBC is 12% in our cohort in Saudi Arabia 
(single institution). In other studies, a similar percentage 
of 11.2% (20) and 12.5% (28) were identified as having 
TNBC using a larger cohort of patients (1601 and over 
50 000 women, respectively). 
In conclusion, the incidence of TBNC in our institu-
tion in Saudi Arabia is similar to that described in other 
countries. These TNBC tumors expressed a significant-
ly higher grade of tumors, with higher expression of CK 
5/6 compared to the non-TNBC control group. These 
tumors were distributed over a wide range of ages, but 
showed no survival difference when compared with oth-
er tumors that are age- and stage-matched. However, we 
have identified that not all TNBC patients had a simi-
lar prognosis. Of the TNBC patients, only the younger 
aged patients were associated with poor prognosis and 
OS compared to those TNBC patients >40 years, 
as well as all non-TNBC patients. Indeed this subset 
of TNBC that are aged ≤40 years, and whose tumor 
showed p53 over-expression and expressed basal CK 
5/6, had aggressive outcomes and were more likely to 
develop brain metastasis (P<.001 and P<.01, respective-
ly). Our cohort provided us with the unique opportunity 
of defining the effect of young age on the worsening of 
prognosis and OS of the TNBC patients. It would be 
worth conducting further analyses in Saudi Arabia to 
compare TNBC patients, covering different age groups 
and different menopausal statuses to get a better under-
standing of the genetic and epigenetic alterations that 
are responsible for the biologically aggressive phenotype 
of these tumors. Long-term studies are needed to exam-
ine whether the prognosis and overall survival of TNBC 
becomes comparable to that of other tumors.
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